See more : Canadian Natural Resources Limited (CNQ) Income Statement Analysis – Financial Results
Complete financial analysis of Infinity Pharmaceuticals, Inc. (INFI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Infinity Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bigeon (BIGN) Income Statement Analysis – Financial Results
- G Mining Ventures Corp. (GMIN.TO) Income Statement Analysis – Financial Results
- Jong Shyn Shipbuilding Co., Ltd. (2644.TWO) Income Statement Analysis – Financial Results
- Komatsu Ltd. (KMTUF) Income Statement Analysis – Financial Results
- African Energy Metals Inc. (NDENF) Income Statement Analysis – Financial Results
Infinity Pharmaceuticals, Inc. (INFI)
About Infinity Pharmaceuticals, Inc.
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.59M | 1.86M | 1.72M | 3.05M | 22.15M | 6.00M | 18.72M | 109.07M | 165.00M | 0.00 | 47.11M | 92.77M | 71.33M | 49.54M | 83.44M | 24.54M | 18.49M | 34.84M | 51.56M | 49.83M | 41.32M | 41.13M | 36.26M | 13.08M | 6.20M | 3.10M | 400.00K | 0.00 |
| Cost of Revenue | 1.56M | 1.12M | 1.04M | 7.31M | 69.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.11M | 29.44M | 31.67M | 35.49M | 24.86M | 9.90M | 7.87M | 2.80M | 1.30M | 200.00K | 0.00 |
| Gross Profit | 1.03M | 738.00K | 682.00K | -4.26M | 22.08M | 6.00M | 18.72M | 109.07M | 165.00M | 0.00 | 47.11M | 92.77M | 71.33M | 49.54M | 83.44M | 24.54M | 18.49M | 9.73M | 22.12M | 18.16M | 5.83M | 16.28M | 26.37M | 5.20M | 3.40M | 1.80M | 200.00K | 0.00 |
| Gross Profit Ratio | 39.72% | 39.72% | 39.67% | -139.69% | 99.69% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 27.93% | 42.91% | 36.44% | 14.10% | 39.57% | 72.71% | 39.78% | 54.84% | 58.06% | 50.00% | 0.00% |
| Research & Development | 32.41M | 31.65M | 26.76M | 27.12M | 19.76M | 20.83M | 119.61M | 199.11M | 143.63M | 99.76M | 118.60M | 108.58M | 99.23M | 77.86M | 47.47M | 33.79M | 35.79M | 3.92M | 4.30M | 2.55M | 6.22M | 12.98M | 8.93M | 3.54M | 5.10M | 4.10M | 2.60M | 600.00K |
| General & Administrative | 13.46M | 14.17M | 12.42M | 14.29M | 14.25M | 21.62M | 42.22M | 37.07M | 29.29M | 27.92M | 27.88M | 0.00 | 21.07M | 19.46M | 16.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.00M | 2.50M | 1.60M | 600.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.46M | 14.17M | 12.42M | 14.29M | 14.25M | 21.62M | 42.22M | 37.07M | 29.29M | 27.92M | 27.88M | 22.72M | 21.07M | 19.46M | 16.84M | 14.03M | 9.46M | 15.07M | 14.10M | 13.96M | 12.27M | 11.02M | 8.41M | 4.44M | 5.00M | 2.50M | 1.60M | 600.00K |
| Other Expenses | 1.56M | 1.12M | 1.04M | 7.31M | 69.00K | -6.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -100.00K | 100.00K | 0.00 | 0.00 |
| Operating Expenses | 45.87M | 45.82M | 39.18M | 41.41M | 34.01M | 42.45M | 161.83M | 236.17M | 172.92M | 127.68M | 146.28M | 131.30M | 120.30M | 97.31M | 64.30M | 47.83M | 45.26M | 24.72M | 19.41M | 17.03M | 70.21M | 30.92M | 30.55M | 8.65M | 10.00M | 6.70M | 4.20M | 1.20M |
| Cost & Expenses | 47.44M | 46.94M | 40.22M | 48.71M | 34.08M | 42.45M | 161.83M | 236.17M | 172.92M | 127.68M | 146.28M | 131.30M | 120.30M | 97.31M | 64.30M | 47.83M | 45.26M | 49.83M | 48.85M | 48.70M | 105.69M | 55.78M | 40.45M | 16.52M | 12.80M | 8.00M | 4.40M | 1.20M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 339.00K | 0.00 | 559.00K | 326.75K | 463.01K | 2.04M | 3.34M | 6.58M | 2.46M | 2.02M | 1.42M | 1.80M | 2.18M | 3.53M | 2.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 180.00K | 180.00K | 2.45M | 2.56M | 93.00K | 1.01M | 1.23M | 1.37M | 9.65M | 0.00 | 1.91M | 1.84M | 1.91M | 1.30M | 21.37K | 188.04K | 1.51M | 4.81K | 6.14K | 40.75K | 144.47K | 279.58K | 1.53M | 0.00 | 300.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 458.00K | 480.00K | 483.00K | 219.00K | 191.00K | 1.72M | 3.42M | 2.29M | 1.77M | 1.82M | 1.64M | 2.10M | 2.18M | 2.15M | 1.97M | 2.81M | 3.69M | 6.23M | 6.71M | 5.29M | 57.04M | 12.60M | 13.20M | 671.71K | 600.00K | 200.00K | 0.00 | 0.00 |
| EBITDA | -44.84M | -44.60M | -38.01M | -45.66M | -11.74M | -43.33M | -30.89M | -127.11M | -7.58M | -125.85M | -52.81M | -36.10M | -48.97B | -47.77B | 24.45M | -20.48M | -26.76B | -16.04B | 9.60M | 8.24M | -64.38B | -14.65B | 17.89M | -2.64M | -5.40M | -4.60M | -4.00M | -1.20M |
| EBITDA Ratio | -1,729.43% | -2,400.59% | -2,211.40% | -1,497.67% | -53.00% | -722.12% | -764.34% | -116.54% | -4.60% | 0.00% | -205.82% | -38.91% | -66.98% | -63.66% | 29.30% | -83.48% | -116.38% | -9.51% | 18.62% | 16.54% | 106.23% | -4.95% | 49.32% | -20.20% | -87.10% | -148.39% | -1,000.00% | 0.00% |
| Operating Income | -44.84M | -45.08M | -38.50M | -45.66M | -11.93M | -36.45M | -30.89M | -127.11M | -7.92M | -127.68M | -52.81M | -38.53M | -48.97M | -47.77M | 19.14M | -23.29M | -26.76M | -16.04M | 2.72M | -748.49K | -64.38M | -14.65M | -4.18M | -3.45M | -6.60M | -4.80M | -4.00M | -1.20M |
| Operating Income Ratio | -1,729.43% | -2,426.43% | -2,239.50% | -1,497.67% | -53.87% | -607.42% | -164.99% | -116.54% | -4.80% | 0.00% | -112.09% | -41.53% | -68.65% | -96.44% | 22.94% | -94.92% | -144.70% | -46.03% | 5.27% | -1.50% | -155.83% | -35.61% | -11.53% | -26.36% | -106.45% | -154.84% | -1,000.00% | 0.00% |
| Total Other Income/Expenses | 475.00K | -179.00K | -2.00M | -1.45M | 676.00K | -6.11M | 790.00K | -933.00K | -9.31M | 896.00K | -1.16M | -1.51M | -713.27K | 14.94M | 4.52M | 6.39M | -598.01K | 2.33M | 1.24M | -1.82M | -51.23M | 3.50B | -8.87M | -133.92K | 300.00K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -44.37M | -45.26M | -40.49M | -47.11M | -11.25M | -42.55M | -30.10M | -128.04M | -17.23M | -126.78M | -53.96M | -40.04M | -49.68M | -32.83M | 23.65M | -16.90M | -27.36M | -13.71M | 3.96M | -2.57M | -115.61M | -14.66M | -13.05M | -3.58M | -6.30M | -4.80M | -4.00M | -1.20M |
| Income Before Tax Ratio | -1,711.11% | -2,436.06% | -2,355.56% | -1,545.13% | -50.81% | -709.17% | -160.77% | -117.40% | -10.44% | 0.00% | -114.54% | -43.16% | -69.65% | -66.28% | 28.35% | -68.87% | -147.94% | -39.35% | 7.68% | -5.16% | -279.82% | -35.64% | -35.98% | -27.39% | -101.61% | -154.84% | -1,000.00% | 0.00% |
| Income Tax Expense | -1.11M | 180.00K | 2.45M | -54.00K | 769.00K | -720.00K | -2.19M | 335.00K | 183.00K | 0.00 | 1.91M | 326.75K | -700.32K | -329.57K | 21.37K | 0.00 | 1.09M | 13.24K | 55.58K | 65.59K | -2.27M | -3.50M | 7.51M | -76.72K | 600.00K | 0.00 | 0.00 | 0.00 |
| Net Income | -43.26M | -45.44M | -42.94M | -47.06M | -11.25M | -41.83M | -30.10M | -128.38M | -17.42M | -126.78M | -53.96M | -40.04M | -48.98M | -32.51M | 23.65M | -16.90M | -28.45M | -14.16M | 3.90M | 1.06M | -62.11M | -11.15M | -11.70M | -3.37M | -6.30M | -4.80M | -4.00M | -1.20M |
| Net Income Ratio | -1,668.18% | -2,445.75% | -2,497.79% | -1,543.36% | -50.81% | -697.17% | -160.77% | -117.70% | -10.56% | 0.00% | -114.54% | -43.16% | -68.67% | -65.62% | 28.35% | -68.87% | -153.82% | -40.66% | 7.57% | 2.13% | -150.34% | -27.10% | -32.25% | -25.78% | -101.61% | -154.84% | -1,000.00% | 0.00% |
| EPS | -0.48 | -0.53 | -0.72 | -0.83 | -0.20 | -0.83 | -0.61 | -2.62 | -0.36 | -2.64 | -1.70 | -1.50 | -1.86 | -1.24 | 1.17 | -0.87 | -3.81 | -6.62 | -18.72 | -26.33 | -71.98 | -1.86 | -3.55 | -11.98 | -31.50 | -48.00 | -40.00 | -0.01 |
| EPS Diluted | -0.48 | -0.53 | -0.72 | -0.83 | -0.20 | -0.83 | -0.61 | -2.62 | -0.36 | -2.64 | -1.70 | -1.50 | -1.86 | -1.24 | 1.14 | -0.87 | -3.81 | -6.62 | -18.72 | -26.33 | -71.98 | -1.86 | -3.55 | -11.98 | -31.50 | -48.00 | -40.00 | -0.01 |
| Weighted Avg Shares Out | 89.25M | 85.60M | 59.86M | 56.98M | 55.41M | 50.56M | 49.61M | 49.08M | 48.56M | 47.94M | 31.71M | 26.62M | 26.32M | 26.20M | 20.24M | 19.51M | 7.46M | 2.14M | 1.82M | 1.29M | 862.93K | 6.00M | 3.29M | 281.26K | 200.00K | 100.00K | 100.00K | 89.02M |
| Weighted Avg Shares Out (Dil) | 89.25M | 85.60M | 59.86M | 56.98M | 55.41M | 50.56M | 49.61M | 49.08M | 48.56M | 47.94M | 31.71M | 26.62M | 26.32M | 26.20M | 20.77M | 19.51M | 7.46M | 2.14M | 6.54M | 6.08M | 862.93K | 6.00M | 3.29M | 281.26K | 200.00K | 100.00K | 100.00K | 89.02M |
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of 10(b)...
Calling all Infinity Pharmaceuticals, Inc. (INFI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Class Action Lawsuit!
NEW YORK , Aug. 24, 2023 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company") (NASDAQ:...
Infinity Pharmaceuticals, Inc. (INFI) Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Infinity Pharmaceuticals, Inc. Securities Class Action
SAN DIEGO--(BUSINESS WIRE)---- $INFI #InfinityPharmaceuticalsInc--Infinity Pharmaceuticals, Inc. (INFI) Misled Investors Regarding its Business Prospects.
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of 10(b)...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Infinity Pharmaceuticals, Inc. - INFI
NEW YORK , Aug. 23, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company") (NASDAQ: INFI). Such investors are advised to contact Robert S.
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 23, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of 10(b)...
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ:INFI) for violations of §§10(b)...
Calling all Infinity Pharmaceuticals, Inc. (INFI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Class Action Lawsuit!
NEW YORK--(BUSINESS WIRE)---- $INFI #classaction--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Infinity Pharmaceuticals, Inc. ("Infinity" or the "Company") (NASDAQ: INFI) and certain of its...
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 21, 2023 /The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Infinity Pharmaceuticals, Inc. ("Infinity" or "the Company") (NASDAQ: INFI) for violations of §§10(b)...
ROSEN, A LEADING LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INFI
NEW YORK , Aug. 20, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) between January 5,...
Source: https://incomestatements.info
Category: Stock Reports